The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Reason given: Poor recruitment
Key facts
- Where
- Pittsburgh, United StatesSee the site
- Phase
- Phase 3
Where in United States
- University of Pittsburgh Medical CenterPittsburgh, United StatesNo longer taking part
Trial details
- Who runs it
- Marissa Jarosinski
- Trial code
- NCT04007055
- Record updated
- 6 July 2026
- Original description
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.Read full original descriptionShow less
The Value of Screening for "High on Treatment Platelet Reactivity" in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
Inclusion: Peripheral arterial disease; Planned angioplasty or stenting of superficial femoral artery or popliteal artery.
Exclusion: Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty); Planned re-stenting at site of prior stent placement; Planned re-angioplasty at site of prior angioplasty; Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center; Current use of oral anticoagulation medication; Patients treated on an emergency basis; Planned intervention at site exclusive of superficial femoral artery or popliteal artery; Known inability to tolerate antiplatelet regimen before enrollment; Current use of prasugrel or ticlopidine; Pregnant patients.